Timothy A Warren1,2,3,4, Benedict Panizza1,2,3, Sandro V Porceddu3,5, Mitesh Gandhi1, Parag Patel1,2, Martin Wood1, Christina M Nagle4, Michael Redmond1. 1. Queensland Skull Base Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 2. Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 3. School of Medicine, University of Queensland, Australia. 4. QIMR Berghofer Medical Research Institute, Brisbane, Australia. 5. Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Abstract
BACKGROUND: Queensland, Australia, has the highest rates of cutaneous squamous cell carcinoma (SCC). Perineural invasion (PNI) is associated with reduced local control and survival. METHODS: A retrospective review of a prospective database of patients with clinical PNI from cutaneous SCC of the head and neck (SCCHN) treated with surgery and postoperative radiotherapy (PORT) between 2000 and 2011 and a minimum of 24 months follow-up. Patients were excluded if immunosuppressed, had non-SCC histology, or were treated palliatively. RESULTS: Fifty patients (mean age, 60 years) with median follow-up of 50 months were included in this study. A total of 54.8% of known primary tumors had incidental PNI. Ten percent had nodal disease at presentation. MRI neurogram was positive in 95.8%. Recurrence-free survival (RFS) at 5-years was 62%. Five-year disease-specific survival (DSS) and overall survival (OS) were 75% and 64%, respectively. There were no perioperative deaths. CONCLUSION: This report demonstrates that long-term survival is achievable in patients with clinical PNI from cutaneous SCCHN after surgery and PORT.
BACKGROUND: Queensland, Australia, has the highest rates of cutaneous squamous cell carcinoma (SCC). Perineural invasion (PNI) is associated with reduced local control and survival. METHODS: A retrospective review of a prospective database of patients with clinical PNI from cutaneous SCC of the head and neck (SCCHN) treated with surgery and postoperative radiotherapy (PORT) between 2000 and 2011 and a minimum of 24 months follow-up. Patients were excluded if immunosuppressed, had non-SCC histology, or were treated palliatively. RESULTS: Fifty patients (mean age, 60 years) with median follow-up of 50 months were included in this study. A total of 54.8% of known primary tumors had incidental PNI. Ten percent had nodal disease at presentation. MRI neurogram was positive in 95.8%. Recurrence-free survival (RFS) at 5-years was 62%. Five-year disease-specific survival (DSS) and overall survival (OS) were 75% and 64%, respectively. There were no perioperative deaths. CONCLUSION: This report demonstrates that long-term survival is achievable in patients with clinical PNI from cutaneous SCCHN after surgery and PORT.
Authors: Yusuf Dundar; Richard B Cannon; Marcus M Monroe; Luke Oliver Buchmann; Jason Patrick Hunt Journal: J Neurol Surg B Skull Base Date: 2016-11-23
Authors: Timothy J Eviston; Elahe Minaei; Simon A Mueller; Navid Ahmadi; Bruce Ashford; Jonathan R Clark; Nicholas West; Ping Zhang; Ruta Gupta; Marie Ranson Journal: Sci Rep Date: 2021-06-23 Impact factor: 4.379